India’s Cadila Healthcare plunges after FDA warns of violations
India's Cadila Healthcare Ltd said it received a U.S. Food and Drug Administration warning for violating manufacturing standards at two of its production facilities, the latest in a series of Indian firms to face such action. The warning letter to Cadila cites issues with its plants in the western Indian state of Gujarat, one of which — the Moraiya facility — makes up about 40 percent of the company&039;s total sales in its largest market, the United States. The FDA inspected the Moraiya facility more than a year ago, highlighting a series of issues with manufacturing processes there, but its observations were not made public.
